Overview
AbOliGo develops a proprietary conjugation platform for fast, reproducible, and customizable antibody-oligonucleotide conjugates (AOCs) used in spatial biology, proteomics, and single-cell workflows. The company offers 3-day delivery on µg-scale production compatible with major multiplexing platforms. Their mission focuses on empowering scientists by addressing bottlenecks in multiomic analysis.
Frequently asked questions
- What are AbOliGo's core capabilities in AOC production?
- AbOliGo provides a proprietary platform for rapid, reproducible, and customizable antibody-oligonucleotide conjugates (AOCs) with 3-day delivery on µg-scale for spatial biology, proteomics, and single-cell applications.
- What platforms are AbOliGo AOCs compatible with?
- AbOliGo AOCs are designed for all major multiplexing platforms in multiomic analysis, including spatial biology and proteomics workflows.
- Where is AbOliGo located?
- AbOliGo is based at Moneta Research Building, Babraham Research Campus, Cambridge, UK.